Zacks: ESSA Pharma Inc. (EPIX) Given Average Rating of “Strong Buy” by Analysts
Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus target price of $5.10 for the company and are forecasting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 110 out of 265 based on the ratings given to its competitors.
A number of analysts have recently weighed in on EPIX shares. Zacks Investment Research raised shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine downgraded shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 7th. Bloom Burton reaffirmed a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. Finally, Dawson James reaffirmed a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd.
Shares of ESSA Pharma (NASDAQ:EPIX) traded up 11.136% on Friday, reaching $0.489. 1,166,006 shares of the company traded hands. ESSA Pharma has a one year low of $0.25 and a one year high of $3.59. The stock’s 50 day moving average price is $0.35 and its 200-day moving average price is $1.43. The stock’s market capitalization is $14.23 million.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.